Clinical Outcomes of Treatment for Laryngeal Cancer at Tokushima University Hospital

In the present retrospective study, a total of 89 patients with laryngeal cancer who had received their primary treatment at the Department of Otolaryngology Head and Neck Surgery, Tokushima University Hospital, between January 2008 and December 2015 were enrolled. The patients consisted of 88 men and one woman, with a median age of 69 years (range 38–90 years). The cancer was located in the glottis in 68 patients and in the supraglottis in 21 patients. The distributions of the T and clinical stages of cancer in the patients with glottic cancer were as follows: T1s/T1a/T1b/T2/T3/T4: 4/26/6/18/10/4 patients; stage I/II/III/IV: 32/18/8/6 patients. The distribution of the T and clinical stages in the patients with supraglottic cancer were as follows: T1/T2/T3/T4: 3/9/7/2 patients; stage I/II/III/IV: 3/6/3/9 patients. Among the patients with glottic cancer, 33 patients underwent radiotherapy alone, 19 underwent chemoradiotherapy, 6 underwent transoral laser microsurgery, and 10 underwent total laryngectomy. Among the patients with supraglottic cancer, 3 patients underwent radiotherapy alone, 10 underwent chemoradiotherapy, 1 underwent vertical partial laryngectomy, and 7 underwent total laryngectomy. The disease-specific survival rate was 98.1% (stage I/II/III/IV: 100%/100%/100%/83.3%) in the patients with glottic cancer and 79.1% (stage I/II/III/IV: 100%/100%/100%/50%) in the patients with supraglottic cancer. The laryngeal preservation rates in the patients with glottic cancer according to the T stage were as follows: T1a, 84.6%; T1b, 66.7%; T2, 83.3%; T3, 30%; T4, 0%.